NAMSA Expands Microbiology Lab in Irvine, California
At NAMSA, we believe that everything we do must be in our clients' best interests. This expansion is one of several examples of that commitment, said Gina Skolmowski, Corporate Vice President of Operations for NAMSA. Through this effort we have optimized our processes to meet increased demand for efficient lot release testing.
The expansion will not impact the delivery of current services, but will provide a more streamlined flow for future testing. The newly expanded space will be used for in vitro toxicology, sterility and bioburden testing. The expansion of these functional areas will also allow for growth in adjacent areas for analytical services and packaging testing. NAMSA is planning an open house to showcase the new features of the facility.
The medical device research, regulatory approval and commercialization process is continuously taking longer and costing more, driving the need for efficiencies wherever possible, and we are very focused on helping our clients meet that need, said Skolmowski.
With recent acquisitions and expansions, NAMSA is well positioned as a fully integrated provider for both medical device manufacturers and human cellular and tissue products (HCT/P). NAMSA has breadth and depth in consulting, non-clinical and clinical services. By having expertise in cardiovascular, orthopedic, ocular, neurologic, gastroenterologic, urologic, combination product and related medical devices, NAMSA helps manufacturers accelerate the process of bringing their products to market.
Tags: Sterility Testing, Bioburden
Date Published: April 2, 2013
Source article link: NAMSA » company contact details